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Surgical site infections (SSIs) are a major threat for liver transplant recipients. We prospec-
tively studied SSIs after living donor liver transplantation (LDLT) at Kyoto University Hospital
from April 2001 to March 2002 (1st period) and from January 2011 to June 2012 (2nd period).
We investigated the epidemiology of SSIs after LDLT and determined the differences
between the two periods. A total of 129 adult recipients (66 during the 1st period and 63 dur-
ing the 2nd period) and 72 pediatric recipients (39 and 33) were included in this study. The
SSI rates for each period were 30.3% (1st period) and 41.3% (2nd period) among the adult
recipients and 25.6% and 30.3% among the pediatric recipients. The overall rates of 30-day
mortality among adult transplant recipients with SSIs were 10.0% (1st period) and 3.9% (2nd
period). No pediatric recipient died from SSIs after LDLT in either period. The incidence of
Enterococcus faecium increased from 5.0% to 26.9% in the adults and from 10.0% to
40.0% in the pediatric patients. Extended-spectrum β-lactamase-producing Enterobacteria-
ceae were emerging important isolates during the 2nd period. For this period, a univariate
analysis showed that ABO incompatibility (P = 0.02), total operation duration (P = 0.01),
graft-to-recipient body weight ratio (GRWR [P = 0.04]), and Roux-en-Y biliary reconstruction
(P<0.01) in the adults and age (P = 0.01) and NHSN risk index (P = 0.02) in the children
were associated with SSI development. In a multivariate analysis, lower GRWR (P = 0.02)
and Roux-en-Y biliary reconstruction (P<0.01) in the adults and older age (P = 0.01) in the
children were independent risk factors for SSIs during the 2nd period. In conclusion, SSIs
caused by antibiotic resistant bacteria may become a major concern. Lower GRWR and
Roux-en-Y biliary reconstruction among adult LDLT recipients and older age among pediat-
ric LDLT recipients increased the risk of developing SSIs after LDLT.
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Introduction
Living donor liver transplantation (LDLT) is a useful strategy for end-stage liver disease and
was initially developed for pediatric liver transplantation [1]. This technique has been used in
adult patients and has been primarily been developed in Asia because of an ongoing critical
shortage of cadaveric grafts [2]. The major indications of LDLT include biliary atresia, other
pediatric liver diseases, and various adult liver diseases (e.g., hepatitis virus-related liver disease
with or without hepatocellular carcinoma [HCC], primary biliary cirrhosis, and primary scle-
rosing cholangitis). Infection is a major complication of liver transplantation because of the
procedure’s technical complexity, long operation duration, and the potential for bacterial con-
tamination from the gastrointestinal tract [3–6]. Surgical site infection (SSI) is one of the most
common infectious complications of liver transplantation, and its incidence has been reported
to be between 18% and 38% [7–9].
We previously conducted a prospective study at Kyoto University Hospital from April 2001
to March 2002 to determine the risk factors for SSIs after LDLTs performed [7]. In the 10 years
since that study, there have been several changes in antimicrobial prophylaxis and immuno-
suppression protocols in LDLT. The previous study revealed the importance of Enterococcus
faecalis as a causative pathogen of SSIs after LDLT. Therefore, in 2003, we changed the periop-
erative antibacterial prophylaxis from flomoxef, an oxacephem antibiotic agent available in
Japan, to ampicillin and cefotaxime to target E. faecalis, as well as Enterobacteriaceae and
methicillin-susceptible Staphylococcus aureus. In the 10 years since, a few studies have reported
the epidemiology and risk factors of SSIs after LDLT, but sufficient data have yet not been
accumulated [10]. The aims of this prospective study were to update the epidemiology of SSIs
after LDLT and determine the differences between the two study periods.
Materials and Methods
Study Population and SSI Definition
We aimed to collect almost the same number of SSI cases at the start of the current study (2nd
period) that we included in our previous study (1st period). The prospective study population
included 129 adult recipients (66 during the 1st period and 63 during the 2nd period) and 72
pediatric recipients (39 and 33) at the Department of Transplantation Surgery, Kyoto University
Hospital. Adults were defined as individuals aged 18 years or older. All recipients who received
an LDLT were prospectively followed by 2 infection control physicians, and all infections from
the time of surgery until 30 days after the LDLT were recorded. All of the data were predefined
and collected using case report forms. We followed up within 30 days after the LDLT. Nine
recipients (5 adult recipients and 4 pediatric recipients during the 1st period) were discharged
within 30 days, and all were followed up at the outpatient department. We included only recipi-
ents who had received a primary LDLT and included only the first episode of SSI in the analyses
for this study. The Institutional Review Board of Kyoto University Hospital approved this study
protocol. No informed consent needed because the data were analyzed anonymously.
SSI was defined in accordance with the Centers for Disease Control and Prevention (CDC)
criteria as described in the previous study and with a criterion of onset within 30 days of surgical
procedures (National Healthcare Safety Network [NHSN] definition) [7,11–13]. An abscess was
defined as a collection of fluid, drained surgically or aspirated under ultrasound guidance, which
showed pus cells upon miroscopy and for which culture yielded one or more organisms. Perito-
nitis was diagnosed if the ascitic fluid neutrophil count was greater than 250 cells/mm3 and if a
pathogen was isolated. In all cases, intraabdominal abscesses were excluded using ultrasound
scanning. Cholangitis was defined when there was one or more clinical indicators of infection
SSIs after Living Donor Liver Transplantation
PLOS ONE | DOI:10.1371/journal.pone.0136559 August 31, 2015 2 / 14
(temperature>38°C or a white blood cell count>15×109 /L) with an otherwise unexplained ele-
vation of liver function tests concomitant with the repeated isolation of an organism in pure cul-
tures from T-tube bile. These 3 types of infections were included in the space/organ criteria. We
included the surgical incision site and the drain site infection as affected areas for SSI.
Antimicrobial Prophylaxis and Immunosuppressive Treatments
Perioperative antibacterial prophylaxis consisted of flomoxef for 72 hr during the 1st period
and ampicillin and cefotaxime for 72 hr during the 2nd period. This represented a major change
in the antibacterial prophylaxis protocol between the two study periods. Trimethoprim and
sulfamethoxazole were administered once daily as a prophylaxis against pneumocystis during
immunosuppressant use. Fluconazole or micafungin was administered after transplantation as
an antifungal prophylaxis at the surgeons’ discretion, and there was no difference in the anti-
fungal prophylaxis used for each patient group and in each study period. The mean duration of
antifungal prophylaxis was 24.8 days. The basic immunosuppression regimen consisted of
tacrolimus and low-dose corticosteroid. Supplemental immunosuppression, when required,
consisted of azathioprine, mizoribine, or mycophenolate mofetil with or without occasional
induction therapy with monocronab-CD3 [7,14]. For ABO-incompatible recipients, a new
immunosuppression protocol has been in use since 2004 [14]. This protocol consists of preop-
erative anti-CD 20 antibodies with preoperative plasma exchange to lower the anti-AB antigen
titer, perioperative mycophenolate mofetil starting 7 days before the LDLT, and continuous
postoperative intraportal administration of steroids until postoperative day 7.
Clinical Characteristics and Risk Factors for SSIs
Demographic data, the potential risk factors for developing SSI, and outcomes were assessed.
The following data were collected in the case reports: (i) pretransplant variables, including,
gender, obesity [adult: body mass index (BMI)> 25; children and adolescents aged 2–19 years:
BMI-for-age charts; and infants: weight-for-length charts], previous Roux-en-Y biliary recon-
struction, previous use of renal replacement therapy, ABO incompatibility, serum albumin
concentration, serum bilirubin concentration, pretransplantation intensive care unit stay (2nd
period), moderate or massive ascites, Child-Pugh score, and Model for End-Stage Liver Disease
(MELD)/Pediatric End-Stage Liver Disease (PELD) score; and (ii) operative and posttransplant
variables, including the duration of transplant surgery, intraoperative red blood cell transfu-
sions, the graft-to-recipient body weight ratio (GRWR, 2nd period), liver segment (2nd period),
type of biliary reconstruction, repeat intraabdominal or intrathoracic surgery, and the NHSN
risk index. Using the NHSN risk index, each operation was scored from 0 to 3 based on the
number of risk factors present in each recipient. These risk factors included having an Ameri-
can Society of Anesthesiologists’ physical status classification score of 3, 4, or 5; an operation
classified as either contaminated or dirty/infected; and an operation that lasted longer than 13
hr, which was the 75th percentile of the duration of 95 consecutive LDLTs performed at our
hospital in 2000.
Statistical Analysis
Statistical analyses were performed using STATA version 11.2 (StataCorp, College Station, TX,
USA). Fisher’s exact or Pearson’s chi-square test was used to compare categorical variables as
appropriate. Student’s t test was used to determine the statistical significance of continuous
variables with a normal distribution, and the Mann-Whitney U test was used to test for the sta-
tistical significance of non-parametric continuous variables. The Kaplan–Meier method was
used for the analysis of the SSI incidence in each study period, and the log-rank test was used
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to compare the difference. Cox proportional hazards models were used to analyze the risk fac-
tors for SSIs. The variables included in multivariate analyses were those that met the criterion
of a P value<0.05 using forward variable selection. In the Cox models, SSIs after an LDLT
were treated as time-dependent variables. The Gronnesby and Borgan test was performed to
determine how well the final model reflected the data from which it was generated. A P value
<0.05 was considered statistically significant.
Results
Characteristics of the Study Population
One hundred twenty-nine adult recipients (66 recipients during the 1st period, and 63 recipi-
ents during the 2nd period) and 72 pediatric recipients (39 recipients during the 1st period, and
33 recipients during the 2nd period) underwent primary LDLT during the two study periods.
The demographic and clinical characteristics of these study patients are shown in Table 1.
(i)Adult recipients. Among the adult recipients, the median age of 2nd period group was
higher than that of the 1st period group (P = 0.03). There was no difference in gender
(P = 0.38). The predominant underlying liver diseases were HCC (27.9%, 36 patients), primary
biliary cirrhosis (13.2%, 17 patients) and chronic hepatitis C (HCV) infection (11.6%, 15
patients). None of these variables showed a significant difference between groups in each
period. The mean Child-Pugh score and MELD/PELD score of the recipients in the 1st period
group were significantly higher than those of the recipients in the 2nd period group (P<0.01
and P = 0.02).
(ii)Pediatric recipients. There was no difference in age and gender between the two study
periods (P = 0.82 and 0.10). The predominant underlying liver diseases were biliary atresia
(73.6%, 53 recipients), and metabolic liver disease (9.7%, 7 recipients). None of these variables
showed a significant difference between groups in each period. The mean Child-Pugh score of
the patients in the 1st period group was significantly higher than that of the recipients in the
2nd period group (P<0.01).
Focus of Surgical Site Infections
(i) Adult recipients. The SSI rates during each study period were 30.3% (20/66) during
the 1st period and 41.3% (26/63) during the 2nd period. Table 2 shows the focus of the SSIs. The
predominant infection site was the organ/space (84.8%). There was no significant difference in
the focus of the SSIs between the two periods.
(ii) Pediatric recipients. The SSI rates were 25.6% (10/39) during the 1st study period and
30.3% (10/33) during the 2nd study period. The predominant infection site was the organ/space
(85.0%).
In each study period, the SSI rates of the adult recipients were higher than those of the pedi-
atric recipients.
Time of Occurrence
Fig 1. shows the cumulative incidence of SSIs after LDLT. No difference was found between
recipient groups in either period (P = 0.30 among the adult recipients and P = 0.72 among the
pediatric recipients).
Pathogens
Table 3 shows the causative pathogens of the SSIs.
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(i) Adult recipients. In total, 63 isolates were identified from 46 SSI patients, including 30
isolates of Gram-positive cocci (GPCs) and 31 isolates of Gram-negative rods (GNRs) and 2
isolates of Gram-positive rods. Eleven episodes during the 1st period and 4 episodes during the
2nd period were polymicrobial infections. All 10 isolates of Staphylococcus aureus (1st period)
and 2 of the 3 isolates of S. aureus (2nd period) were resistant to methicillin. The incidence of
Table 1. Demographic and clinical characteristics of the study patients.
Patient characteristics Adult recipients Pediatric recipients
2001–2002 2011–2012 Overall P value 2001–2002 2011–2012 Overall P value
(n = 66) (n = 63) (n = 129) (n = 39) (n = 33) (n = 72)
Pretransplant variables
Median age (range), years 48.5(18–69) 52(19–69) 50(18–69) 0.03 1(0.17–17) 2(0.08–17) 1(0.08–17) 0.82
Gender, female/male 31/35 35/28 66/63 0.38 24/15 13/20 37/35 0.10
Obesity, n (%) 20(30.3%) 14(22.2%) 34(26.4%) 0.32 2(5.1%) 0 2(2.8%) 0.50
Underlying liver disease, n (%)
Biliary atresia 3(4.6%) 7(11.1%) 10(7.8%) 0.20 31(79.5%) 22(66.7%) 53(73.6%) 0.29
HCC 19(28.9%) 17(27.0%) 36(27.9%) 0.85 0 0 0 -
Primary biliary cirrhosis 7(10.6%) 10(15.9%) 17(13.2%) 0.44 0 0 0 -
Hepatitis C 8(12.1%) 7(11.1%) 15(11.6%) 1.00 0 0 0 -
Fulminant hepatic failure 7(10.6%) 4(6.4%) 11(8.5%) 0.53 2(5.1%) 3(9.1%) 5(6.9%) 0.66
Primary sclerosing cholangitis 5(7.6%) 3(4.8%) 8(6.2%) 0.88 2(5.1%) 1(3.0%) 3(4.2%) 1.00
Metabolic liver disease 6(9.1%) 1(1.6%) 7(5.4%) 0.12 3(7.7%) 4(12.1%) 7(9.7%) 0.70
Neoplastic liver disease other than HCC 2(3.0%) 1(1.6%) 3(2.3%) 1.00 1(2.6%) 3(9.1%) 4(5.6%) 0.33
Hepatitis B 3(4.6%) 1(1.6%) 4(3.1%) 0.62 0 0 0 -
Other 6(9.1%) 12(19.1%) 18(14.0%) - 0 0 0 -
Dialysis, n (%) 3(4.6%) 28(44.4%) 31(24.0%) <0.01 0 4(12.1%) 4(5.6%) 0.04
Ascites, n (%) 42(63.6%) 50(79.4%) 92(71.3%) 0.05 25(64.1%) 17(51.5%) 42(58.3%) 0.34
Previous Roux-en-Y biliary reconstruction, n (%) 5(7.6%) 5(7.9%) 10(7.8%) 1.00 34(87.2%) 21(63.6%) 55(76.4%) 0.03
ABO incompatibility, n (%) 12(18.2%) 21(33.3%) 33(25.6%) 0.07 4(10.3%) 4(12.1%) 8(11.1%) 1.00
Serum albumin concentration (mean ± SD), g/dL 3.1±0.7 3.1±0.5 3.1±0.6 0.80 3.5±0.6 3.4±0.7 3.5±0.6 0.65
Serum bilirubin concentration (mean ± SD), mg/dL 11.0±11.4 8.8±10.2 9.9±10.8 0.27 11.5±8.6 9.4±10.7 10.5±9.6 0.36
Pretransplantation ICU care, n (%) NA 4(6.4%) NA NA NA 0 NA NA
Child-Pugh score (mean ± SD) 11.3±2.6 9.5±1.9 10.4±2.4 <0.01 10.2±2.4 8.2±2.3 9.3±2.6 <0.01
MELD/PELD score (mean ± SD) 22.0±9.2 18.7±7.1 20.3±8.4 0.02 15.7±10.1 14.0±7.5 14.9±9.0 0.43
Operative and post-transplant variables
Total operation duration (mean ± SD), min 713±159 855±200 782±194 <0.01 609±128 716±124 658±136 <0.01
Intraoperative RBC transfusion (mean ± SD), mL/kg 50.0±104 40.8±48.0 45.5±81.7 0.53 70.6±75.4 32.1±37.7 52.9±63.7 0.01
GRWR (mean ± SD), % NA 0.94±0.22 NA NA NA 2.5±1.3 NA NA
Segment (right), n (%) NA 35(55.6%) NA NA NA 1(3.0%) NA NA
Roux-en-Y biliary construction, n (%) 15(22.7%) 23(36.5%) 38(29.5%) 0.12 39(100%) 29(87.9%) 68(94.4%) 0.04
Repeat intraabdominal or intrathoracic surgery, n (%) 15(22.7%) 11(17.4%) 26(20.2%) 0.52 6(15.4%) 5(15.2%) 11(15.3%) 1.00
NHSN risk index 0.04 0.27
0, n (%) 7(10.6%) 2(3.2%) 9(7.0%) 6(15.4%) 7(21.2%) 13(18.1%)
1, n (%) 34(51.5%) 23(36.5%) 57(44.2%) 30(76.9%) 20(60.6%) 50(69.4%)
2, n (%) 23(34.9%) 36(57.1%) 59(45.7%) 3(7.7%) 6(18.2%) 9(12.5%)
3, n (%) 2(3.0%) 2(3.2%) 4(3.1%) 0 0 0
HCC, hepatocellular carcinoma; ICU, intensive care unit; MELD, Model for End-Stage Liver Disease; PELD, Pediatric End-Stage Liver Disease; GRWR,
graft-to-recipient body weight ratio; NHSN National Healthcare Safety Network; NA, not analyzed. Bold type indicates statistically signiﬁcant P values.
doi:10.1371/journal.pone.0136559.t001
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SSIs caused by methicillin-resistant Staphylococcus aureus (MRSA) decreased significantly
between the 2 study periods (P<0.01). Of the Enterococcus spp., E. faecium was the major caus-
ative pathogen (87.5% of enterococci) during the 2nd period, whereas 1 of 6 enterococci were E.
faecium during the 1st period (P = 0.11). None of the enterococci were resistant to vancomycin.
The GNRs included 9 isolates (19.6%) of Pseudomonas aeruginosa, 6 isolates (13.0%) of Entero-
bacter spp., 4 isolates (8.7%) of Escherichia coli, and 2 isolates (7.7%) of Klebsiella spp. Two of 3
E. coli isolates (66.7%) and 1 of 2 Klebsiella spp. isolates (50.0%) were extended-spectrum β-lac-
tamase (ESBL) producers, all of which were isolated during the 2nd study period.
(ii) Pediatric recipients. In total, 21 isolates were identified from 20 SSI patients, includ-
ing 14 isolates of GPCs and 7 isolates of GNRs. Regarding causative pathogens, no significant
difference was found between the two periods. One episode during the 2nd period was a poly-
microbial infection. Only 1 isolate (25.0%) of E. faecium was found to be a causative pathogen
during the 1st period, and the incidence of SSIs caused by E. faecium was increased to 80.0% (4/
5 isolates) during the 2nd period; in comparison, 1 of 6 enterococci during the 1st period were
E. faecium (P = 0.30). These findings are similar to those for the adult patients. None of the
enterococci were resistant to vancomycin. One isolate of ESBL-producing E. coli was found
during the 2nd study period.
Risk Factors for SSIs
To determine the risk factors for SSIs, we examined 12 pretransplant variables, 6 operative and
posttransplant variables, and the NHSN risk index.
(i) Adult recipients. A reanalysis of the previous data showed that gender (P<0.01) and
Roux-en-Y biliary reconstruction (P = 0.04) were risk factors for SSIs during the 1st period in
the univariate analyses (Table 4). The multivariate analysis revealed that male recipients (rela-
tive risk [RR] 6.12; 95% confidence interval [CI] 1.79–20.9; P<0.01) and Roux-en-Y biliary
reconstruction (RR 2.48; 95% CI 1.01–6.07; P = 0.04) were independent risk factors for SSIs
after LDLT during the 1st period (Table 5).
During the 2nd period, ABO incompatibility (P = 0.02), longer operation duration
(P = 0.01), lower GRWR (P = 0.04), and Roux-en-Y biliary reconstruction (P<0.01) were sig-
nificantly associated with SSIs after LDLT (Table 4) in the univariate analysis. As a result of
goodness-of-fit testing, we selected 3 of these 4 variables (ABO incompatibility, GRWR, and
Roux-en-Y biliary reconstruction) for inclusion in the multivariate analysis. Lower GRWR (RR
7.72; 95% CI 1.33–44.9; P = 0.02) and Roux-en-Y biliary reconstruction (RR 3.18; 95% CI
1.44–7.04; P<0.01) emerged as independent risk factors for SSI after LDLT (Table 5).
(ii) Pediatric recipients. In the univariate analysis, age (P = 0.04) and repeat operation
(P = 0.03) were significantly associated with SSI (Table 6), and repeat operation was the only
independent risk factor (RR 4.75; 95% CI 1.32–17.0; P = 0.02) that emerged during the 1st
period (Table 7).
Table 2. Site of infection after living donor liver transplantation.
Infection site Adult recipients Pediatric recipients
No. of episodes (%) P value No. of episodes (%) P value
2001–2002 2011–2012 Overall 2001–2002 2011–2012 Overall
(n = 20) (n = 26) (n = 46) (n = 10) (n = 10) (n = 20)
Superﬁcial 2(10.0%) 1(3.9%) 3(6.5%) 0.57 0 0 0 -
Deep 2(10.0%) 2(7.7%) 4(8.7%) 1.00 3(30.0%) 0 3(15.0%) 0.47
Organ/space 16(80.0%) 23(88.5%) 39(84.8%) 0.68 7(70/0%) 10(100%) 17(85.0%) 0.47
doi:10.1371/journal.pone.0136559.t002
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During the 2nd period, age (P = 0.01) was also a significant risk factor for SSI in the univari-
ate analysis (Table 6); furthermore, this age was independent risk factor (RR 1.14; 95% CI
1.02–1.26; P = 0.01 [Table 7]).
Fig 1. Cumulative incidence of surgical site infection after living donor liver transplantation. This figure indicates the cumulative incidence of SSIs (A:
adult recipients and B: pediatric recipients). P values (determined with a Log-rank test) are indicated in each graph. SSI, surgical site infection; LDLT living
donor liver transplantation.
doi:10.1371/journal.pone.0136559.g001
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Prognosis
Seventeen of the adult recipients with SSI died (37.0%, 17/46 patients) in the hospital. However,
overall 30-day mortalities were 10.0% (2/20 SSI patients) for the 1st period group and 3.9% (1/
26 SSI patients) for the 2nd period group.
None of the pediatric patients with SSI died within 30 days during either of the two periods.
Discussion
SSIs after LDLT are a major complication, with an incidence ranging from 30% to 40% [7,15].
This high incidence is similar to previously reported incidences but higher than the rates after
cadaveric liver transplantation reported by Hellinger et al (16%) and Park et al (11.2%)
[8,9,16]. Hellinger et al explained that the differences in the SSI incidences reported in our
Table 3. Causative pathogens of surgical site infection after living donor liver transplantation.
Pathogen Adult recipients Pediatric recipients
No. of isolates (%) P value No. of isolates (%) P value
2001–2002 2011–2012 Overall 2001–2002 2011–2012 Overall
(20 episodesa) (26 episodesb) (46 episodes) (10 episodes) (10 episodesc) (20 episodes)
Gram-positive cocci 18 12 30 5 9 14
Staphylococcus aureus 10(50.0%) 3(11.5%) 13(28.26%) <0.01 1(10.0%) 2(20.0%) 3(15.0%) 1.00
MRSA 10(50.0%) 2(7.7%) 12(26.1%) <0.01 1(10.0%) 3(20.0%) 3(15.0%) 1.00
Enterococcus spp.d 6(30.0%) 8(30.8%) 14(30.4%) 1.00 4(40.0%) 5(50.0%) 9(45.0%) 1.00
E. faecalis 4(20.0%) 1(3.9%) 5(10.9%) 0.15 2(20.0%) 0 2(10.0%) 0.47
E. faecium 1(5.0%) 7(26.9%) 8(17.4%) 0.11 1(10.0%) 4(40.0%) 5(25.0%) 0.30
Other Enterococcus spp. 1(5.0%) 0 1(2.2%) 0.44 1(10.0%) 1(10.0%) 2(10.0%) 1.00
Coagulase-negative staphylococci 1(5.0%) 1(3.9%) 3(6.5%) 0.57 0 1(10.0%) 1(5.0%) 1.00
MRCNS 0 1(3.9%) 1(2.2%) 1.00 0 1(10.0%) 1(5.0%) 1.00
Other 1e(5.0%) 0 0 0 1f(10.0%) 1(5.0%) 1.00
Gram-negative rods 12 19 31 5 2 7
Pseudomonas aeruginosa 4(20.0%) 5(19.2%) 9(19.6%) 1.00 2(20.0%) 1(10.0%) 3(15.0%) 1.00
Enterobacter spp. 3(15.0%) 3(11.5%) 6(13.0%) 1.00 2(20.0%) 0 2(10.0%) 0.47
Escherichia coli 1(5.0%) 3(11.5%) 4(8.7%) 0.62 0 1(10.0%) 1(5.0%) 1.00
Escherichia coli (ESBL) 0 2(7.7%) 2(4.4%) 0.50 0 0 0 -
Klebsiella spp. 0 2(7.7%) 2(4.4%) 0.50 1(10.0%) 0 1(5.0%) 1.00
Klebsiella spp. (ESBL) 0 1(3.9%) 1(2.2%) 1.00 0 0 0 -
Other 4g(20.0%) 5h(19.2%) 9(19.6%) 0.71 0 0 0 -
Gram-positive rods 0 2(7.7%) 2(4.4%) 0.50 0 0 0 -
SSI, surgical site infection; MRSA, methicillin-resistant Staphylococcus aureus; MRCNS, methicillin-resistant coagulase-negative staphylococci. Bold type
indicates statistically signiﬁcant P values.
aIncluding 11 episodes of polymicrobial infection.
bIncluding 4 episodes of polymicrobial infection.
cIncluding 1 episode of polymicrobial infection.
dVancomycin resistance was not observed.
eIncluding a single isolate of Streptococcus intermedius.
fIncluding a single isolate of the Streptococcus vestibularis
gIncluding a single isolate of Acinetobacter baumannii, Aeromonas caviae, and Chryseobacterium indologenes, and 2 isolates of Serratia marcescens.
hIncluding a single isolate of Acinetobacter baumannii, Aeromonas hydrophila, Sphingomonas paucimobilis, and Bacteroides uniformis.
doi:10.1371/journal.pone.0136559.t003
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prior study and their study mainly resulted from case definitions and times of infection onset.
They suggested that it was necessary to consider the possibility of risk factors in addition to
surgical procedures for infections that occurred more than 30 days after liver transplantation.
We included SSIs that had occurred more than 30 days after an LDLT in our previous study.
Therefore, we defined SSIs according to the NHSN system and reanalyzed the data of the 1st
period. The SSI rate after LDLT seems to be higher than the rate of after cadaveric liver trans-
plantation [8,9,16,17]. The difficulty of the surgical procedure might be one reason for this
finding. The total operation duration in our study was longer than those reported in other stud-
ies of cadaveric live transplantation [9,16]. Relative to these other studies, our study also
involved a higher mean intraoperative red blood cell transfusion volume [9,16]. Furthermore,
the MELD/PELD scores in our study were higher than those reported in previous studies
[8,18]. These factors cannot be discounted as risk factors for SSI after LDLT because they
affected most of the patients examined in this study. Another reason for the higher incidence is
possible over-diagnosis. The diagnosis of cholangitis is occasionally difficult in LDLT recipients
because its signs, including fever, increased serum bilirubin levels and liver enzyme elevation,
are similar to those of patients experiencing graft rejection. Although two infection-control
doctors diagnosed cholangitis, the possibility of over-diagnosis should be considered.
Table 4. Univariate analysis of risk factors for SSIs in 129 adult living donor liver transplant recipients.
Variables 2001–2002 2011–2012
SSIs All others P value RR 95% CI SSIs All others P value RR 95% CI
n = 20 n = 46 n = 26 n = 37
Pretransplant variables
Age, mean ± SD 42.8±15.4 44.8±11.6 0.65 0.99(0.96–1.03) 49.2±13.5 48.5±13.0 0.87 1.00 (0.97–1.03)
Gender, female/male 3/17 28/18 <0.01 6.16(1.80–21.1) 11/15 17/20 0.70 0.85 (0.38–1.90)
Obesity, n (%) 4(20.0%) 16(34.8%) 0.27 0.54(0.18–1.61) 8(30.8%) 6(16.2%) 0.12 1.95 (0.84–4.52)
Previous Roux-en-Y biliary reconstruction, n (%) 3(15.0%) 2(4.4%) 0.16 2.31(0.68–7.90) 3(11.5%) 2(5.4%) 0.37 1.73 (0.52–5.80)
Dialysis, n (%) 0 3(6.5%) 13(50.0%) 15(40.5%) 0.60 1.23 (0.56–2.70)
ABO incompatibility, n (%) 6(30.0%) 6(13.0%) 0.16 2.23(0.85–5.81) 13(50.0%) 8(21.6%) 0.02 2.59 (1.18–5.70)
Serum albumin concentration (mean ± SD), g/dL 3.2±0.72 3.0±0.68 0.55 1.22(0.65–2.29) 3.1±0.5 3.1±0.6 0.98 1.01 (0.51–2.01)
Serum bilirubin concentration (mean ± SD), mg/dL 9.9±13.7 11.5±10.4 0.19 0.99(0.94–1.03) 7.8±8.2 9.6±11.5 0.39 0.98 (0.93–1.03)
Pretransplantation ICU care, n (%) NA NA NA NA 1(3.9%) 3(8.1%) 0.51 0.51 (0.07–3.79)
Ascites, n (%) 12(60.0%) 30(65.2%) 0.72 0.85(0.35–2.08) 19(73.1%) 31(83.8%) 0.22 0.58 (0.24–1.39)
Child-Pugh score (mean ± SD), point 11.0±2.5 11.4±2.6 0.36 0.93(0.80–1.09) 9.4±1.8 9.5±1.9 0.61 0.95 (0.77–1.17)
MELD/PELD (mean ± SD), point 21.6±11.4 22.1±8.3 0.83 0.99(0.95–1.05) 17.6±6.1 19.4±7.7 0.23 0.96 (0.91–1.02)
Operative and post-transplant variables
Total operation duration (mean ± SD), min 743±171 700±154 0.40 1.00(0.99–1.00) 929±231 804±161 0.01 1.00 (1.00–1.01)
Intraoperative RBC transfusion (mean ± SD), mL/kg 62.2±91.2 44.6±110.2 0.63 1.00(0.99–1.00) 44.5±60.1 38.2±38.2 0.75 1.00 (0.99–1.00)
GRWR (mean ± SD), % NA NA NA NA 0.88±0.20 0.99±0.23 0.04 7.37 (1.03–52.8)
Segment (right), n (%) NA NA NA NA 16(61.5%) 19(51.4%) 0.48 1.33 (0.60–2.97)
Roux-en-Y biliary construction, n (%) 8(40.0%) 7(15.2%) 0.04 2.51(1.02–6.15) 15(36.5%) 8(21.6%) <0.01 2.90 (1.31–6.40)
Repeat intraabdominal or intrathoracic surgery, n (%) 7(35.0%) 8(17.4%) 0.11 2.13(0.85–5.34) 7(26.9%) 4(10.8%) 0.05 2.40 (0.99–5.75)
NHSN risk index 0.18 1.54(0.87–2.90) 0.74 0.90 (0.49–1.67)
0, n (%) 1(5.0%) 6(13.0%) 1(3.9%) 1(2.7%)
1, n (%) 10(50.0%) 24(52,2%) 10(38.5%) 13(35.4%)
2, n (%) 8(40.0%) 15(32,.6%) 14(53.9%) 22(59.5%)
3, n (%) 1(5.0%) 1(2.2%) 1(3.9%) 1(2.7%)
SSI, surgical site infection; RR, relative risk; MELD, Model for End-Stage Liver Disease; PELD, Pediatric End-Stage Liver Disease; RBC, red blood cell;
GRWR, graft-to-recipient body weight ratio; NHSN National Healthcare Safety Network; NA, not analyzed. Bold type indicates statistically signiﬁcant P
values.
doi:10.1371/journal.pone.0136559.t004
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Given the high incidence of SSI observed in this study, the overall 30-day mortality rates
among SSI patients were extremely low. Earlier intervention by an infection control-team may
improve the prognosis of SSI after LDLT. Further investigations should be conducted to assess
this finding.
S. aureus and enterococci were the two major GPCs identified as causative pathogens
among the LDLT recipients with SSIs. Although the incidence of SSIs caused by E. faecalis
decreased, the incidence of SSIs caused by E. faecium during the 2nd period increased to 26.9%
compared with 5.0% during the 1st period, among the adult recipients. Among the pediatric
recipients, SSIs caused by E. faecium also increased, from 10.0% to 40.0%. The perioperative
antibacterial prophylaxis changes that were initiated in 2003 appeared to be associated with
this increased incidence of E. faecium. In a previous study of bacteremia after liver transplanta-
tion, E. faecalis was the major causative species among enterococcal bacteremia [19]. In that
study, only flomoxef was used as perioperative antibacterial prophylaxis throughout the entire
study period. These findings suggest that prophylaxis directed specifically against E. faecalis
may decreases the incidence of SSIs caused by E. faecalis but may increase the incidence of E.
faecium SSIs after LDLT.
Regarding the GNRs identified as causative pathogens of SSIs after LDLT, it is notable that
ESBL producers were detected among E. coli and Klebsiella spp. during the 2nd period. Other
studies have reported infectious complications caused by ESBL-producing Enterobacteriaceae
after liver transplantation [20,21]. Third-generation cephalosporins, which usually have no effect
against ESBL producers, are commonly used as a perioperative prophylaxis in liver transplanta-
tion worldwide [19,22]. Therefore, ESBL producers could become a serious problem in the near
future from the standpoint of the prevention and control of SSIs after LDLT. Previous studies
revealed that the unnecessary use of antimicrobials has resulted in the emergence and dissemina-
tion of antibiotic-resistant nosocomial pathogens and that antimicrobial prophylaxis after
wound closure was typically unnecessary [23]. The prolonged use of prophylactic antimicrobials
for perioperative prophylaxis is among the major unnecessary uses of antibiotics. The Surgical
Infection Prevention Project recommended that prophylactic antimicrobials be discontinued
within 24 hr after the end of surgery [24]. Therefore, 72 hr of perioperative antimicrobial use
could contribute to an increased incidence of drug-resistant pathogens, such as ESBL-producing
Enterobacteriaceae and E. faecium. Our current antimicrobial prophylactic strategy, especially
the duration of prophylactic antimicrobial use, should be considered an improvement.
Previous studies have reported that the risk factors for SSIs after liver transplantation include
choledochojejunal or hepaticojejunal reconstruction, reoperation, prolonged intraoperative
Table 5. Multivariate analysis of risk factors for SSIs in 129 adult living donor liver transplant
recipients.
Variables P value RR (95% CI)
2001–2002 (n = 66)
Gender (male) <0.01 6.12 (1.79–20.9)
Roux-en-Y biliary reconstruction 0.04 2.48 (1.01–6.07)
2011–2012 (n = 63)
ABO incompatibility, n (%) 0.16 1.83 (0.80–4.20)
GRWR (mean±SD), 1% decrement 0.02 7.72 (1.33–44.9)
Roux-en-Y biliary reconstruction <0.01 3.18 (1.44–7.04)
SSI, surgical site infection; RR, relative risk; GRWR, graft-to-recipient body weight ratio. Bold type indicates
statistically signiﬁcant P values.
doi:10.1371/journal.pone.0136559.t005
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time, posttransplant renal replacement therapy, and a high pretransplantation model for the
end-stage liver disease score [17,25,26]. In this study, Roux-en-Y biliary reconstruction was an
independent risk factor for SSIs after LDLT among the adult recipients in both periods. Other
independent risk factors, including lower GRWR among the adults recipients, age, repeat sur-
gery among the pediatric recipients were also similar to the previous report [17,26]. Although
we identified some significant risk factors for SSIs after LDLT, these variables appeared to be
unmodifiable. Unfortunately, the change in antimicrobial prophylaxis from flomoxef to ampi-
cillin and cefotaxime did not appear to contribute to a reduction of SSIs or an improvement of
the prognosis. There were no differences in the incidence of SSIs after LDLT between the two
periods. Further studies are needed to determine modifiable risk factors and an effective preven-
tion strategy for reducing the incidence and improving the outcome of SSIs after LDLT. Fur-
thermore, consideration of improved SSI management and prophylactic strategies is important
for reducing the mortality of SSIs. Earlier antimicrobial intervention based on the results of sur-
veillance cultures might play a key role in preventing and managing SSIs [27].
Certain limitations of this study should be noted. First, although, we conducted the multi-
variate analysis to determine the risk factors for SSIs in each study group, a small number of
Table 6. Univariate analysis of risk factors for SSIs in 72 pediatric living donor liver transplant recipients.
Variables 2001–2002 2011–2012
SSIs All others P value RR 95% CI SSIs All others P value RR 95% CI
n = 10 n = 29 n = 10 n = 23
Pretransplant variables
Age, mean ± SD 6.2±6.8 2.8±3.9 0.04 1.11(1.01–1.23) 7.3±7.5 3.0±3.1 0.01 0.04 (1.03–1.26)
Gender, female/male 7/3 17/12 0.51 0.63(0.16–2.45) 5/5 8/15 0.50 0.65 (0.19–2.24)
Obesity, n (%) 0 2(6.9%) 0 0
Previous Roux-en-Y biliary reconstruction, n (%) 10 24(82.8%) 8(80.0%) 13(56.5%) 0.28 2.36 (0.50–11.1)
Dialysis, n (%) 0 0 1(10.0%) 3(13.0%) 0.86 0.83 (0.10–6.55)
ABO incompatibility, n (%) 2(20.0%) 2(6.9%) 0.32 2.19(0.46–10.3) 2(20.0%) 2(8.7%) 0.37 2.02 (0.43–9.57)
Serum albumin concentration (mean ± SD), g/dL 3.7±0.5 3.4±0.6 0.10 3.16(0.80–12.6) 3.2±0.8 3.5±0.6 0.16 0.49 (0.19–1.31)
Serum bilirubin concentration (mean ± SD), mg/dL 8.8±8.8 12.4±8.5 0.23 0.95(0.88–1.03) 14.4±12.2 7.2±9.4 0.12 1.04 (0.99–1.09)
Pretransplantation ICU care, n (%) NA NA NA NA 0 0
Ascites, n (%) 5(50.0%) 20(69.0%) 0.27 0.50(0.14–1.72) 5(50.0%) 12(52.2%) 0.91 0.93 (0.27–3.21)
Child-Pugh score (mean ± SD), point 9.5±2.3 10.4±2.5 0.28 0.87(0.68–1.12) 8.7±2.4 8.0±2.3 0.40 1.12 (0.85–1.50)
MELD/PELD (mean ± SD), point 11.9±6.7 10.7±10.9 0.17 0.94(0.87–1.02) 16.2±6.4 13.1±7.9 0.30 1.04 (0.96–1.13)
Operative and post-transplant variables
Total operation duration (mean ± SD), min 639±180 598±107 0.30 1.00(0.99–1.01) 774±154 691±102 0.15 1.00 (0.99–1.00)
Intraoperative RBC transfusion (mean ± SD), mL/kg 59.4±69.1 74.4±78.3 0.36 0.99(0.99–1.01) 32.7±30.7 31.8±41.0 0.90 0.99 (0.98–1.01)
GRWR (mean ± SD) NA NA NA NA 2.1±1.3 2.6±1.2 0.23 1.42 (0.80–2.56)
Segment, right NA NA NA NA 1(10.0%) 0
Roux-en-Y biliary construction, n (%) 10(100%) 29(100%) 9(90.0%) 20(87.0%) 0.86 1.21 (0.15–9.53)
Repeat intraabdominal or intrathoracic surgery, n (%) 4(40.0%) 2(6.9%) 0.03 4.75(1.33–17.0) 3(30.0%) 2(8.7%) 0.19 2.49 (0.64–9.65)
NHSN risk index 0.49 1.63(0.41–6.48) 0.02 3.38 (1.20–9.51)
0, n (%) 1(10.0%) 5(17.2%) 0 7(30.4%)
1, n (%) 8(80.0%) 22(75.9%) 6(60.0%) 14(60.9%)
2, n (%) 1(10.0%) 2(6.9%) 4(40.0%) 2(8.7%)
3, n (%) 0 0 0 0
SSI, surgical site infection; RR, relative risk; MELD, Model for End-Stage Liver Disease; PELD, Pediatric End-Stage Liver Disease; RBC, red blood cell;
GRWR, graft-to-recipient body weight ratio; NHSN National Healthcare Safety Network; NA, not analyzed. Bold type indicates statistically signiﬁcant P
values.
doi:10.1371/journal.pone.0136559.t006
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SSIs could have caused instability in the multivariable logistic regression model. Second, this
study was conducted at a single center. The emergence of drug-resistant pathogens may be
affected by the rate of resistant pathogens at our institute or in this area. Our institute is located
in the Kyoto-Shiga region, and in this area, the rate of ESBL-producing E. coli has increased
obviously in recent years [28].
In conclusion, the incidence of SSIs after LDLT remains very high. The incidence of E. fae-
cium SSIs has increased noticeably, and we should pay attention to ESBL-producing Entero-
bacteriaceae as causative pathogens of SSIs after LDLT. This study revealed that Roux-en-Y
biliary reconstruction was an independent risk factor for SSIs after LDLT in the adult patients.
Lower GRWR was also an independent risk factor for SSI in the adults. These risk factors were
similar to those reported in previous studies. To improve the SSI rate and the mortality of SSIs,
changing only the prophylactic antimicrobials is not sufficient. The creation of a stricter or
more individualized strategy for preventing and managing SSIs, including via prophylaxis and
management, is urgently needed.
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